A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses
- Conditions
- Healthy
- Interventions
- Drug: JNJ-77474462Drug: Placebo
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT04544826
- Locations
- 🇦🇺
Nucleus Network, Q-Pharm Pty Ltd, Herston, Australia
A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: MilvexianBiological: 4-Factor Prothrombin Complex Concentrate (4F-PCC)Biological: Recombinant Human Factor VIIa (rFVIIa)Biological: Placebo matching to 4F-PCCBiological: Placebo matching to rFVIIa
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 52
- Registration Number
- NCT04543383
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Study of JNJ-77474462 in Healthy Participants
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 78
- Registration Number
- NCT04544813
- Locations
- 🇦🇺
Nucleus Network, Q-Pharm Pty Ltd, Herston, Australia
A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT04540744
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- Drug: JNJ-75348780
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 147
- Registration Number
- NCT04540796
- Locations
- 🇦🇺
Austin Hospital, Heidelberg, Australia
🇰🇷The Catholic University of Korea Seoul St Marys Hospital, Seoul, Korea, Republic of
🇮🇱Sheba Medical Center, Ramat Gan, Israel
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 308
- Registration Number
- NCT04538664
- Locations
- 🇲🇽
Centro Oncologico de Chihuahua, Chihuahua, Mexico
🇺🇸City of Hope, Duarte, California, United States
🇺🇸University of California Irvine, Orange, California, United States
A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
- Conditions
- Hepatitis D, Chronic
- Interventions
- Drug: JNJ-73763989Drug: Entecavir (ETV) monohydrateDrug: PlaceboDrug: Tenofovir alafenamide (TAF)Drug: Tenofovir disoproxil
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 52
- Registration Number
- NCT04535544
- Locations
- 🇯🇵
National Hospital Organization Shikoku Cancer Center, Iizuka-shi, Japan
🇺🇸Stanford University School of Medicine, Redwood City, California, United States
🇺🇸Harvard Medical School Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 588
- Registration Number
- NCT04533529
- Locations
- 🇨🇿
Neuroterapie KH S R O, Kutna Hora, Czechia
🇨🇿A Shine S R O, Plzen, Czechia
🇨🇿Medical Services Prague S R O, Praha 6, Czechia
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 212
- Registration Number
- NCT04532749
- Locations
- 🇦🇷
STAT Research S A, Ciudad Autonoma de Buenos Aires, Argentina
🇺🇸Altea Research Institute, Phoenix, Arizona, United States
🇺🇸Preferred Research Partners, Little Rock, Arkansas, United States
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 108
- Registration Number
- NCT04523207
- Locations
- 🇺🇸
Urological Research Network, Hialeah, Florida, United States
🇺🇸Arkansas Urology, Little Rock, Arkansas, United States
🇺🇸MidLantic Urology, Bala-Cynwyd, Pennsylvania, United States